DMK PHARMACEUTICALS Corp: Nasdaq/NYSE listing notice — DMK Pharmaceuticals receives Nasdaq delisting notice for failing to meet $35M market value requirement

DMK PHARMACEUTICALS Corp

On Oct 11, 2023, DMK received Nasdaq delisting notice for failing to maintain minimum $35M market value for 30 consecutive trading days.
Company plans to timely request a hearing before Nasdaq Hearings Panel to stay delisting.
Previously, on Apr 12, 2023, DMK was given 180 days to regain compliance, which expired Oct 9, 2023.
No assurance that panel will grant continued listing or that DMK will regain compliance.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

DMK PHARMACEUTICALS Corp received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: market value
Rules: 5550(b)(2)

Exact text from the filing

October 11, 2023, the Company received notice from the Staff that the Company’s common stock was subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company plans to timely request a hearing before the Panel, which request will stay any further action by Nasdaq at least until the hearing is held and any extension the Panel may grant to the Company following the hearing expires. There can be no assurance, however, that the Panel will grant the Company’s request for continued listing or that the Company will regain compliance with

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001387131-23-012324

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.